


SUPPLEMENTAL INFORMATION

Chemistry

Experiment Procedures

General: Unless otherwise noted, all reactants or reagents including dry solvents were obtained from commercial suppliers and used as received. Unless otherwise noted, all reactions were performed with dry solvents under an atmosphere of nitrogen in dried glassware using standard vacuum-line techniques. All work-up and purification procedures were carried out with reagent-grade solvents in air. Analytical thin-layer chromatography (TLC) was performed using E. Merck silica gel 60 F₂₅₄ precoated plates (0.25 mm). The developed chromatogram was analyzed by UV lamp (254 nm). Flash column chromatography was performed with E. Merck silica gel 60 (230–400 mesh). Preparative thin-layer chromatography (PTLC) was performed using Wako gel B5-F silica coated plates (0.75 mm) prepared in our laboratory. A reverse phase thin-layer chromatography (TLC) was performed using E. Merck silica gel 60 RP-18 F₂₅₄S precoated plates (0.25 mm). The high-resolution mass (HRMS) spectra were conducted on Thermo Fisher Scientific Exactive. Nuclear magnetic resonance (NMR) spectra were recorded on a JEOL JNM-ECA-400 (¹H 400 MHz, ¹³C 100 MHz) and JEOL JMN-ECA-600II with Ultra COOL™ probe (¹H 600 MHz, ¹³C 150 MHz) spectrometer. Chemical shifts for ¹H NMR are expressed in parts per million (ppm) relative to tetramethylsilane (δ 0.00 ppm). Chemical shift for ¹³C NMR are expressed in ppm relative to CDCl₃ (δ 77.0 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = triplet, m = multiplet, br = broad signal), coupling constant (Hz), and integration.




26
27

28 **Fig S1. Synthesis of glycosyl donors GD1 and GD2**

29 Reagents and reaction conditions: I) acetyl chloride, allyl alcohol, 70°C, 10 h; II)
 30 TsOH \oplus H₂O, benzaldehyde dimethyl acetal, 50°C, 3 h; III) NaH, benzyl bromide
 31 (BnBr), DMF, 0°C then room temperature (RT), overnight; IV) TsOH \oplus H₂O, MeOH,
 32 CH₂Cl₂, RT; V) TrCl, DMAP, pyridine, 50°C, overnight; VI) NaH, R-X (methyl iodide
 33 or BnBr), DMF, 0°C then RT, overnight; VII) TsOH \oplus H₂O, MeOH, CH₂Cl₂, RT; VIII)
 34 AZADO, (diacetoxyiodo)benzene, buffer, CH₂Cl₂, 0°C, 3 h; IX) KHCO₃, BnBr,
 35 tetrabutylammonium iodide (TBAI), DMF, RT, 4 h; X) PdCl₂, sodium acetate, H₂O,
 36 acetic acid, RT, 48 h; XI) Ac₂O, Et₃N, CH₂Cl₂, RT, 4 h; XII) 4-MeC₆H₄-SH (tol-SH),
 37 BF₃ \oplus Et₂O, CH₂Cl₂, 0°C to RT, 3 h.

38 Ts = tosyl, DMF = N,N-dimethylformamide, Tr = triphenylmethyl, DMAP =
39 N,N-dimethyl-4-aminopyridine, AZADO = 2-aza-adamantane N-oxyl.

40



41


42 **Fig S2.** Synthesis of glycosyl donor **GD3**

43 Reagents and reaction conditions: I) NaH, BnBr, DMF, 0°C then RT, overnight; II)

44 PdCl₂, sodium acetate, H₂O, acetic acid, RT, 48 h; III) Ac₂O, Et₃N, CH₂Cl₂, RT, 4 h;

45 IV) 4-MeC₆H₄-SH (tol-SH), BF₃⊕Et₂O, CH₂Cl₂, 0°C to RT, 3 h.

46




47

48 **Fig S3.** Synthesis of glycosyl acceptor **GA1** and **GA2**

49 Reagent and reaction conditions: I) TrCl, pyridine, 50°C, overnight; II) BnBr, NaH,

50 DMF, 0°C then RT, 8 h; III) TsOH⊕H₂O, MeOH, CH₂Cl₂, RT.

51




52

53 **Fig S4.** Synthesis of glycosyl acceptor **GA3**

54 Reagents and reaction conditions: I) BnBr, NaH, DMF, 0°C then RT, 3 h; II) (±)-CSA,
 55 acetone dimethylacetal, RT, overnight; III) MeOH, H₂O, reflux, 48 h; IV) BnBr, NaH,
 56 DMF, 0°C then RT, overnight; V) HOAc, H₂O, 65°C, 2 h; VI) Bu₂SnO, MeOH, reflux,
 57 overnight; VII) PMB-Cl, TBAB, MS4Å, benzene, reflux, 6 h; VIII) BnBr, NaH, DMF,
 58 0°C then RT, overnight; IX) DDQ, CH₂Cl₂, H₂O, RT, 1 h.

59 CSA = camphorsulfonic acid, TBAB = tetrabutylammonium bromide, PMB-Cl =
 60 *para*-methoxy benzyl chloride, MS = molecular sieves, DDQ =
 61 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

62




63


64 **Fig S5.** Synthesis of glycosyl acceptor **GA4**

65 Reagents and reaction conditions: I) BnBr, NaH, DMF, 0°C then RT, 3 h; II)
 66 2,3-butanedione, trimethyl orthoformate, (±)-CSA, MeOH, reflux, 20 h; III) allyl

67 bromide, NaH, DMF, 0°C then RT, 3 h; IV) TFA, CH₂Cl₂, RT, 15 min; V) BnBr, NaH,
 68 DMF, 0°C then RT, overnight; VI) PdCl₂, sodium acetate, H₂O, acetic acid, RT, 48 h.
 69 TFA = trifluoroacetic acid
 70




71



72

73 **Fig S6.** Programmable glycosylation of glycosyl donor and acceptor, the yields of
74 glycosylation product **G'** and the deprotection product **G** (the total yield of two
75 anomers and ratio of β : α is shown in parenthesis)
76 Reagent and reaction conditions: I) NIS, TfOH (cat.), CH₂Cl₂, -40 °C then RT, 4 h;
77 II) Pd(OH)₂/C, H₂ atm., EtOAc, MeOH, RT, overnight.

78
79
80
81
82




85 **Fig S7.** Synthesis of 4,6-Me-GlcA- β (1,6)-Gal (**G9**)

86 Reagents and reaction conditions: I) TMSCHN₂, MeOH, toluene, RT, 30 min

87 TMSCHN₂ = trimethylsilyldiazomethane

88




89

90 **Fig S8.** Synthesis of 4-Me-GlcA- β -OMe (**G11**)

91 Reagents and reaction conditions: I) $\text{TsOH}^{\oplus}\text{H}_2\text{O}$, benzaldehyde dimethyl acetal,
 92 50°C , 3 h; II) NaH, benzyl bromide (BnBr), DMF, 0°C then room temperature (RT),
 93 overnight; III) $\text{TsOH}^{\oplus}\text{H}_2\text{O}$, MeOH, CH_2Cl_2 , RT; IV) TrCl, DMAP, pyridine, 50°C ,
 94 overnight; V) NaH, Me-I, DMF, 0°C then RT, overnight; VI) $\text{TsOH}^{\oplus}\text{H}_2\text{O}$, MeOH,
 95 CH_2Cl_2 , RT; VII) AZADO, (diacetoxyiodo)benzene, buffer, CH_2Cl_2 , 0°C , 3 h; VIII)
 96 $\text{Pd}(\text{OH})_2/\text{C}$, H_2 atm., EtOAc, MeOH, RT, overnight.

97 **Preparation of glycosyl donor GD1** (Fig. S1)

98 Benzyl(2*S*,3*S*,4*S*,5*R*)-4,5-bis(benzyloxy)-3-methoxy-6-(*p*-tolylthio)tetrahydro-2*H*-py-
 99 ran-2-carboxylate



100 **GD1**

100

101 The treatment of **7a** (ref. 1S) (239 mg, 0.50 mmol) with acetic anhydride (2 mL)
 102 and triethylamine (2 mL) under ambient condition smoothly afforded the
 103 corresponding acetyl glycoside **8a** within 4 h (the completion of the reaction was

104 monitored by TLC). The reaction mixture was concentrated *in vacuo*, yielding a
105 viscous residue, which was further purified by flash column chromatography
106 (hexane/EtOAc = 5:1) to give **8a** as an oil liquid.

107 A dry CH₂Cl₂ was added to a Schlenk tube containing **8a** (ca. 0.50 mmol) and
108 Tol-SH (74.0 mg, 0.60 mmol, 1.2 equiv.) under a N₂ atmosphere, and the reaction
109 mixture was cooled down to 0 °C before catalytic amount of BF₃⊕Et₂O 1M in Et₂O
110 (10 μL, 0.01 mmol, 0.02 equiv.) was added dropwise to the mixture. The reaction
111 mixture was stirred for 3 h at RT and then cooled to 0 °C before 100 μL of
112 triethylamine was added slowly to quench the reaction. After that, the mixture was
113 allowed to increase to RT and concentrated *in vacuo*. The resultant viscous residue
114 was subjected to silica gel column chromatography (hexane/EtOAc = 5:1) to afford
115 **GD1** as a colorless viscous liquid (mixture of two anomers) in 195 mg (0.34 mmol,
116 67% yield in 2 steps).


117 ¹H NMR (CDCl₃, 400 MHz) δ 2.30 (s, 3H), 2.32 (s, 1H, these two singlets are –Me in
118 –tolyl group of two anomers), 3.37 (s, 1H), 3.41 (s, 3H, these two singlets are
119 4-O-Me group of two anomers), 3.48–3.51 (m, 1H), 3.57–3.59 (m, 0.3H), 3.76–3.84
120 (m, 2H) 4.56–4.92 (m, 6H), 5.21 (q, *J* = 12.4 Hz, 2.5H), 5.48 (d, *J* = 5.2 Hz, 0.7H),
121 7.01 (d, *J* = 7.9 Hz, 1.9H), 7.05 (d, *J* = 7.9 Hz, 0.7H), 7.29–7.37 (m, 23H).

122 ¹³C NMR (CDCl₃, 100 MHz) δ 21.1, 60.5, 60.6, 67.1, 67.2, 70.8, 72.6, 75.4, 75.6,
123 75.7, 77.9, 79.0, 80.0, 80.7, 81.1, 81.5, 85.8, 87.9, 88.2, 127.6, 127.8(5), 127.9,
124 128.1, 128.2, 128.3, 128.3(8), 128.4(2), 128.5, 129.7, 132.8, 133.1, 135.2, 137.5,
125 137.7, 138.2, 138.5, 98.7, 127.7, 127.9, 128.0, 128.2, 128.4, 137.3, 137.4, 137.7,
126 138.2, 138.5, 169.1.

127

128 **Preparation of glycosyl donor GD2** (Fig. S1)

129 ((2*S*,3*R*,4*S*,5*R*)-6-(Allyloxy)-3-benzyl-4,5-bis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)m
130 ethanol



5b

131


132 To a stirred solution of trityl ether **4** [ref. S1] (2.57 g, 4.0 mmol) in DMF (60 mL), a
 133 60% dispersion of NaH in mineral oil (240 mg, 6.0 mmol, 1.5 equiv.) was added at
 134 0°C. After stirring the mixture for 30 min, benzyl bromide (BnBr: 710 μ L, 6.0 mmol)
 135 was added, and the resultant mixture was stirred for a further 3 h at RT. After
 136 adding MeOH (1.5 equiv.) to stop the reaction, the reaction mixture was extracted
 137 three times with H₂O/EtOAc/hexane (2:1:1, 15 mL) to remove DMF, and dried over
 138 Na₂SO₄. After filtration of the organic layer, the mixture was concentrated in *vacuo*.
 139 The resultant crude product was dissolved in MeOH/CH₂Cl₂ (1:1, 30 mL) to obtain a
 140 yellow solution, which was treated with TsOH·H₂O (10 mol%) and stirred at RT for 6
 141 h. NaHCO₃ was added to neutralize the solution and the resultant yellow solution
 142 was concentrated in *vacuo*, and then subjected to flash column chromatography
 143 (hexane/EtOAc = 3:1) to yield alcohol **5b** as a yellow syrup (1.67 g, 3.4 mmol, 85%
 144 yield).

145 ¹H NMR (CDCl₃, 400 MHz) δ 3.50–3.56 (m, 2H), 3.65–3.78 (m, 3H), 3.97–4.06 (m,
 146 2H), 4.14 (dd, *J* = 13.2, 5.2 Hz, 1H), 4.65 (dd, *J* = 12.0, 5.2 Hz, 2H), 4.74–4.91 (m,
 147 4H) 4.93–5.02 (m, 1H), 5.23 (d, *J* = 10.4 Hz, 1H), 5.33 (d, *J* = 17.2 Hz, 1H), 5.88–
 148 5.97 (m, 1H), 7.29–7.37 (m, 15H).

149 ¹³C NMR (CDCl₃, 100 MHz) δ 61.8, 68.2, 70.8, 73.2, 75.0, 75.7, 79.9, 81.9, 95.6,
 150 118.2, 127.8, 127.9, 128.0, 128.3, 128.3(8), 128.4(2), 133.6, 138.1, 138.7.

151

152 Benzyl(2*S*,3*S*,4*S*,5*R*)-6-(allyloxy)-3,4,5-tris(benzyloxy)tetrahydro-2*H*-pyran-2-carbo
 153 xylate



154 **6b**


155 To a solution of **5b** (980 mg, 2.0 mmol,) in CH₂Cl₂ (4 mL) and buffer
 156 (Na₂HPO₄/NaH₂PO₄, pH = 7), iodobenzene diacetate (1.29 g, 4.0 mmol) was added
 157 at 0°C, followed by addition of 2-azaadamantane *N*-oxyl (AZADO: 15.0 mg, 0.1
 158 mmol, 0.1 equiv.). The mixture was stirred at the same temperature (the completion
 159 of the reaction was monitored by TLC). After 2 h, **5b** was consumed and then the
 160 reaction mixture was extracted three times with CH₂Cl₂ and water. The organic
 161 layer was dried over Na₂SO₄ and the solvent was removed *in vacuo*. A yellow liquid
 162 was obtained, to which was added dry DMF (5 mL), followed by KHCO₃ (1.0 g, 10.0
 163 mmol, 5.0 equiv.), BnBr (710 μL, 6.0 mmol, 3.0 equiv.), and tetrabutylammonium
 164 iodide (TBAI: 74.0 mg, 0.20 mmol, 0.1 equiv.). After stirring at RT for 3 h, the
 165 reaction mixture was extracted three times with EtOAc/H₂O (1:1, 10 mL). The
 166 organic layer was concentrated *in vacuo*, and the residue was purified by silica gel
 167 column chromatography (hexane/EtOAc = 5:1) to yield **6b** as a colorless oil liquid
 168 (713 mg, 1.2 mmol, 60% yield).

169 ¹H NMR (CDCl₃, 400 MHz) δ 3.57–3.63 (m, 1H), 3.74 (t, *J* = 10.0 Hz, 1H), 3.99–
 170 4.06 (m, 2H), 4.18 (dd, *J* = 13.2, 5.2 Hz, 1H), 4.26–4.32 (m, 1H), 4.42–4.47 (m, 1H),
 171 4.62–4.67 (m, 1H), 4.71–4.85 (m, 4H), 4.92–4.99 (m, 1H), 5.11–5.23 (m, 3H), 5.28–
 172 5.35 (m, 1H), 5.86–5.96 (m, 1H), 7.10–7.15 (m, 2H), 7.21–7.25 (m, 3H), 7.29–7.34
 173 (m, 15H)

174 ¹³C NMR (CDCl₃, 100 MHz) δ 67.2, 68.6, 70.5, 73.4, 75.0, 75.8, 79.2, 79.6, 81.3,
 175 96.1, 118.7, 127.6, 127.7, 127.8(8), 127.9(2), 128.1, 128.2, 128.3, 128.3(7),
 176 128.4(1), 128.5, 133.2, 135.0, 137.8, 137.9, 138.5, 169.5

177

178 Benzyl(2*S*,3*S*,4*S*,5*R*)-3,4,5-tris(benzyloxy)-6-hydroxytetrahydro-2*H*-pyran-2-carbox
 179 ylate



7b

180


181 A mixture of **6b** (594 mg, 1.0 mmol), sodium acetate (205 mg, 2.5 mmol, 2.5
 182 equiv.), PdCl₂ (212 mg, 1.2 mmol, 1.2 equiv.), and aqueous acetic acid (acetic
 183 acid/H₂O = 11:1, 12 mL) was stirred at RT for 48 h. After removing acetic acid and
 184 water in *vacuo*, the residue was subjected to silica gel column chromatography
 185 (hexane/EtOAc = 3:1) to afford **7b** as a white amorphous solid (421 mg, 0.76 mmol,
 186 76% yield).

187 ¹H NMR (CDCl₃, 400 MHz) δ 3.11 (s, 1H), 3.60 (dd, *J* = 9.2, 3.2 Hz, 1H), 3.76 (t, *J* =
 188 9.6 Hz, 1H), 3.95–4.03 (m, 1H), 4.49 (dd, *J* = 16.0, 9.6 Hz, 2H), 4.65–4.80 (m, 4H),
 189 4.86–4.93 (m, 1H), 5.09–5.23 (m, 3H), 7.12–7.15 (m, 2H), 7.25–4.26 (m, 3H), 7.29–
 190 7.32 (m, 15H)

191 ¹³C NMR (CDCl₃, 100 MHz) δ 67.2, 70.5, 73.3, 74.8, 75.6, 79.1, 79.3, 80.6, 91.5,
 192 127.6, 127.7, 127.9, 128.0, 128.0(5), 128.1(1), 128.2, 128.3, 128.5, 128.6, 134.9,
 193 137.5, 137.7, 138.3, 169.6

194

195 Benzyl(2*S*,3*S*,4*S*,5*R*)-3,4,5-tris(benzyloxy)-6-(*p*-tolylthio)tetrahydro-2*H*-pyran-2-car
 196 boxylate



GD2

197

198 Same procedures as the preparation of **GD1**: treatment of **7b** (277 mg, 0.50
 199 mmol) with acetic anhydride (2 mL) and triethylamine (2 mL) under ambient
 200 condition, smoothly afforded the corresponding acetyl glycoside **8b** within 4 h (the
 201 completion of the reaction was monitored by TLC). The reaction mixture was
 202 concentrated *in vacuo*, yielding a viscous residue, which was subjected to flash
 203 column chromatography (hexane/EtOAc = 5:1) to give **8b** as an oil liquid,.

204 A dry CH₂Cl₂ was added to a Schlenk tube containing **8b** (ca. 0.50 mmol) and
205 Tol-SH (74.0 mg, 0.60 mmol, 1.2 equiv.) under a N₂ atmosphere, and the reaction
206 mixture was cooled down to 0 °C before catalytic amount of BF₃⊕Et₂O 1M in Et₂O
207 (10 μL, 0.01 mmol, 0.02 equiv.) was added dropwise to the mixture. The reaction
208 was stirred for 3 h at RT and cooled to 0 °C before 100 μL of triethylamine was
209 added slowly to quench the reaction. After that, the mixture was allowed to increase
210 to RT and concentrated *in vacuo*, afforded a viscous residue, which was purified by
211 silica gel column chromatography (hexane/EtOAc = 5:1) to afford **GD2** as a
212 colorless viscous liquid as a mixture of two anomers (254 mg, 0.39 mmol, 77% yield
213 in 2 steps).


214 ¹H NMR (CDCl₃, 400 MHz) δ 2.31 (s), 2.33 (s) (3H) (these two singlets are –Me in –
215 tolyl group of two anomers), 3.49 (t, *J* = 9.2 Hz), 3.69 (t, *J* = 9.2 Hz) (1H) (these two
216 triplets are one isomeric proton from two anomers) 3.81–3.86 (m, 1H), 3.89–3.95 (m,
217 1H), 4.49–4.62 (m, 1H), 4.67–4.97 (m, 6H), 5.09–5.22 (m, 2H), 5.51 (s, 1H), 7.02–
218 7.08 (m, 2H), 7.13–7.17 (m, 2H), 7.28–7.40 (m, 20H).

219 ¹³C NMR (CDCl₃, 100 MHz) δ 21.1, 67.2, 67.3, 70.9, 72.6, 75.0, 75.1, 75.4, 75.8,
220 75.9, 78.1, 79.0, 79.1(5), 79.2(2), 80.1, 81.6, 85.9, 87.9, 88.3, 127.7, 127.7(7),
221 127.8(0), 128.0, 128.2, 128.3, 128.3(6), 128.4(4), 128.5, 128.6, 128.9, 129.5, 129.7,
222 132.8, 133.1, 135.1, 137.5, 137.7, 137.8, 137.9, 138.1, 138.4, 168.0, 169.1.

223

224 Preparation of glycosyl donor **GD3** (Fig. S2)

225 Benzyl(2*S*,3*S*,4*S*,5*R*)-3,4,5-tris(benzyloxy)-6-(*p*-tolylthio)tetrahydro-2*H*-pyran-2-car
226 boxylate



227

6c

228 To a stirred solution of trityl ether **5a** [ref. S1] (828 mg, 2.0 mmol) in DMF (30 mL),
229 a 60% dispersion of NaH in mineral oil (120 mg, 3.0 mmol, 1.5 equiv.) was added at


230 0°C. After stirring the mixture for 30 min, benzyl bromide (355 μ L, 3.0 mmol, 1.5
231 equiv.) was added, and the resultant mixture was stirred for a further 3 h at RT.
232 MeOH (1.5 equiv.) was then added to stop the reaction. The reaction mixture was
233 extracted three times with H₂O/EtOAc/hexane (2:1:1, 10 mL) to remove DMF, and
234 dried over Na₂SO₄. After filtration of the organic layer, the mixture was concentrated
235 in *vacuo*. The resultant crude product was purified by flash column chromatography
236 (hexane/EtOAc= 3:1) to yield **6c** as a colorless oil liquid (907 mg, 0.18 mmol, 90%
237 yield).

238 ¹H NMR (CDCl₃, 400 MHz) δ 3.46 (s, 3H), 3.48–3.55 (m, 1H), 3.61–3.74 (m, 4H),
239 3.89 (t, *J* = 9.6 Hz, 1H), 3.98–4.03 (m, 1H), 4.13–4.18 (m, 1H), 4.49–4.65 (m, 3H),
240 4.74–4.81 (m, 3H), 4.88–4.96 (m, 1H), 5.10 (dd, *J* = 1.6, 1.0 Hz, 1H), 5.28–5.33 (m,
241 1 H), 5.88–5.98 (m, 1H), 7.27–7.40 (m, 15H)

242 ¹³C NMR (CDCl₃, 100 MHz) δ 60.6, 68.1, 68.5, 70.2, 73.2, 73.4, 75.6, 79.4, 79.6,
243 82.0, 95.6, 118.1, 127.5, 127.6, 127.8, 127.9, 128.0, 128.1, 128.2(5), 128.2(8),
244 128.3, 133.7, 138.0, 138.2, 138.9

245

246 (3*R*,4*S*,5*R*,6*R*)-3,4-Bis(benzyloxy)-6-((benzyloxy)methyl)-5-methoxytetrahydro-2*H*-
247 pyran-2-ol



248

7c


249 A mixture of **6c** (504 mg, 1.0 mmol), sodium acetate (205 mg, 2.5 mmol, 2.5
250 equiv.), PdCl₂ (212 mg, 1.2 mmol, 1.2 equiv.), and aqueous acetic acid (acetic
251 acid/H₂O = 11:1, 12 mL) was stirred at RT for 48 h. After removing acetic acid and
252 water in *vacuo*, the residue was subjected to silica gel column chromatography
253 (hexane/EtOAc = 3:1) to afford **7c** as a white amorphous solid (348 mg, 0.75 mmol,
254 75% yield).

255 ¹H NMR (CDCl₃, 400 MHz) δ 3.28–3.38 (m, 1H), 3.47 (s, 3H), 3.51–3.55 (m, 1H),

256 3.63–3.74 (m, 2H), 3.85 (t, $J = 9.6$ Hz, 1H), 3.91–3.95 (m, 1H), 4.50–4.95 (m, 7H),
257 5.20 (d, $J = 3.6$ Hz, 1H), 7.29–7.39 (m, 15H).
258 ^{13}C NMR (CDCl_3 , 100 MHz) δ 60.6, 68.6, 70.1, 73.1, 73.4, 75.5, 79.5, 79.6, 79.7,
259 81.5, 91.2, 127.5(7), 127.6(3), 127.8, 127.9, 128.0, 128.1, 128.3, 128.4, 130.1,
260 137.8, 138.6

261

262 (3*R*,4*S*,5*R*,6*R*)-3,4-Bis(benzyloxy)-6-((benzyloxy)methyl)-5-methoxy-2-(*p*-tolylthio)t
263 etrahydro-2*H*-pyran



264 **GD3**

265 Same procedures as the preparation of **GD1** and **GD2** (Fig. S1): treatment of **7c**
266 (232 mg, 0.50 mmol) with acetic anhydride (2 mL) and triethylamine (2 mL) under
267 ambient condition, smoothly afforded the corresponding acetyl glycoside **8c** within 4
268 h (the completion of the reaction was monitored by TLC). The reaction mixture was
269 concentrated *in vacuo*, yielding a viscous residue, which was subjected to flash
270 column chromatography (hexane/EtOAc = 5:1) to give **8c** as an oil liquid.

271 A dry CH_2Cl_2 was added to a Schlenk tube containing **8c** (ca. 0.50 mmol) and
272 Tol-SH (74.0 mg, 0.60 mmol, 1.2 equiv.) under a N_2 atmosphere. The reaction
273 mixture was cooled down to 0 °C before catalytic amount of $\text{BF}_3 \oplus \text{Et}_2\text{O}$ 1M in Et_2O
274 (10 μL , 0.01 mmol, 0.02 equiv.) was added dropwise to the mixture. The mixture
275 was stirred for 3 h at RT and cooled to 0 °C before 100 μL of triethylamine was
276 added slowly to quench the reaction. After that, the mixture was allowed to increase
277 to RT and concentrated *in vacuo* to afford a viscous residue which was purified by
278 silica gel column chromatography (hexane/EtOAc = 5:1) to afford **GD3** as a
279 colorless viscous liquid as a mixture of two anomers (158 mg, 0.33 mmol, 65% yield
280 in 2 steps).


281 ^1H NMR (CDCl_3 , 400 MHz) δ 2.29 (s), 2.31 (s) (3H) (these two singlets are –Me in –

282 tolyl group of two anomers), 3.49 (s), 3.51 (s) (3H) (these two singlets are –Me in 4–
283 O-Me group of two anomers) 3.57–3.65 (m, 1H), 3.72–3.85 (m, 2H), 4.26 (dd, $J =$
284 8.0, 2.0 Hz 1H), 4.45 (d, $J = 12.4$ Hz, 1H), 4.56–4.89 (m, 6H), 4.96 (d, $J = 10.8$ Hz,
285 1H), 5.55 (d, $J = 5.2$ Hz, 1H), 7.01–7.06 (m, 2H), 7.28–7.38 (m, 17H).
286 ^{13}C NMR (CDCl_3 , 100 MHz) δ 21.3, 60.9, 68.8, 69.3, 71.2, 72.6, 73.5, 75.5, 75.8,
287 75.9, 79.2, 79.3, 79.7, 79.9, 80.7, 82.6, 86.8, 87.5, 87.7, 127.7, 127.9, 128.0, 128.1,
288 128.1(7), 128.2(4), 128.3, 128.4, 128.5, 128.6, 129.8, 130.8, 132.2, 132.8, 137.3,
289 137.9, 138.2, 138.6, 138.9

290

291 **Preparation of glycosyl donor GA1 and GA2** (Fig. S3)

292 ((2*R*,3*S*,4*S*,5*R*)-3,4,5,6-Tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methanol



293

GA1

294 Triphenylmethyl chloride (306 mg, 1.1 mmol) was added to a stirred solution of
295 D-galactose (180 mg, 1.0 mmol) in pyridine (2 mL), and the mixture was heated at
296 50 °C for overnight to afford a yellow suspension. MeOH (1.5 equiv.) was added to
297 quench the reaction, affording yellow solution, which was concentrated *in vacuo*.
298 The resultant syrup was purified by flash column chromatography (EtOAc/MeOH =
299 4:1) to give crude trityl ether, a white fluffy solid, as the precursor of **GA1**, which can
300 be used for next step.


301 A stirred suspension of crude trityl ether in dry DMF (5 mL) was added NaH (60%
302 in mineral oil, 60.0 mg, 1.5 mmol) in 2 portions at 0 °C, and stirred for 30 min,
303 followed by treatment of benzyl bromide (178 μL , 1.5 mmol, 1.5 equiv.), stirred for 8
304 h at RT, MeOH (1.5 equiv.) was added to quench the reaction slowly until no gas
305 was formed. After extracted 2 times with EtOAc/ H_2O (1:1, 10 mL), the organic layer
306 was concentrated *in vacuo*. The $\text{CH}_2\text{Cl}_2/\text{MeOH}$ solution of the yielded mixture was
307 added TsOH· H_2O (15 mol%) then it was stirred at RT for overnight. The solution

308 was neutralized with NaHCO₃, and organic solvent was removed in *vacuo* to afford
309 a crude viscous liquid. Column chromatography (hexane/EtOAc = 3:1) yielded
310 glycosyl acceptor **GA1** (254 mg, 0.47 mmol, 47% yield) as a white solid.

311 ¹H NMR (CDCl₃, 400 MHz) δ 2.13–2.16 (m, 1H), 3.58–3.67 (m, 2H), 3.72–3.78 (m,
312 1H), 4.06–4.10 (m, 2H), 4.34 (t, *J* = 7.2 Hz, 1H), 4.48 (dd, *J* = 12.4, 7.2 Hz, 2H),
313 4.56–4.65 (m, 3H), 4.71–4.83 (m, 3H), 4.98 (d, *J* = 2.0 Hz, 1H), 7.27–7.36 (m, 20H).
314 ¹³C NMR (CDCl₃, 100 MHz) δ 61.5, 69.1, 72.3, 72.7, 81.0, 83.8, 98.7, 127.7, 127.9,
315 128.0, 128.2, 128.4, 137.3, 137.4, 137.7, 138.3.

316

317 ((2*R*,3*R*,4*S*,5*R*)-3,4,5,6-Tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methanol



318

GA2

319 **GA2** as a white solid (270 mg, 0.50 mmol, 50% yield) was prepared from D-glucose
320 (180 mg, 1.0 mmol) in the same procedures as **GA1** described above.


321 ¹H NMR (CDCl₃, 400 MHz) δ 1.85 (t, *J* = 7.2 Hz, 1H), 3.34–3.39 (m, 1H), 3.49 (t, *J* =
322 8.0 Hz, 1H), 3.57 (t, *J* = 9.6 Hz, 1H), 3.67–3.73 (m, 2H), 3.85–3.90 (m, 1H), 4.56–
323 4.88 (m, 6H), 4.91–5.00 (m, 3H), 7.25–7.38 (m, 20H).

324 ¹³C NMR (CDCl₃, 100 MHz) δ 62.0, 71.6, 74.9(5), 75.0(2), 75.7, 77.5, 82.3, 84.5,
325 102.8, 127.6, 127.7, 127.8(5), 127.9(1), 128.0, 128.1, 128.3, 128.4, 128.5, 137.2,
326 137.9, 138.2, 138.4.

327

328 **Preparation of glycosyl donor GA3** (Fig. S4)

329 (3*R*,4*S*,5*R*,6*R*)-2-(Benzyloxy)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol



330

9a


331 To a stirred solution of D-glucose [ref. S2] (1.8 g, 10.0 mmol) in DMF (30 mL), a
332 60% dispersion of NaH in mineral oil (400 mg, 10.0 mmol, 1.0 equiv.) was added at
333 0°C. After stirring the mixture for 30 min, benzyl bromide (BnBr: 140 μ L, 1.2 mmol,
334 1.2 equiv.) was added to the resultant mixture, stirred for a further 3 h at RT; MeOH
335 (1.2 equiv.) was then added to stop the reaction. The reaction mixture was
336 concentrated in *vacuo*, followed by flash column chromatography (EtOAc/MeOH =
337 4:1) to yield **9a** as an amorphous white solid (1.30 g, 4.8 mmol, 48% yield).

338 ^1H NMR (CD_3OD , 400 MHz) δ 3.30 (t, J = 1.2 Hz, 1H), 3.43–3.51 (m, 2H), 3.58 (dd,
339 J = 10.0, 8.0 Hz, 1H), 3.71–3.89 (m, 4H), 4.30 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 12.0
340 Hz, 1H), 4.83–4.94 (m, 3H), 7.25–7.33 (m, 3H), 7.41 (d, J = 7.2 Hz, 2H).

341 ^{13}C NMR (CD_3OD , 100 MHz) δ 62.5, 70.2, 71.6, 72.5, 74.9, 76.6, 103.8, 128.6,
342 129.1, 129.2, 139.1

343

344 (3a*S*,4*R*,7*R*,7a*R*)-6-(Benzyloxy)-4-(hydroxymethyl)-2,2-dimethyltetrahydro-4*H*-[1,3]
345 dioxolo[4,5-*c*]pyran-7-ol



346

10a


347 (\pm)-CSA (51.0 mg, 0.22 mmol, 0.05 equiv.) was added to a solution of **9a** (1.20 g,
348 4.4 mmol) in acetone dimethylacetal (35 mL) and the solution was stirred overnight
349 at room temperature. The reaction mixture was treated with triethylamine and
350 concentrated to a residue, which was then dissolved in a mixture of MeOH/ H_2O
351 10:1 (35 mL) and refluxed for 48 h. The reaction mixture was concentrated to a
352 residue, which was subjected to silica gel column chromatography (hexane/EtOAc
353 = 1:1) to yield **10a** as a white solid (1.27 g, 4.1 mmol, 93% yield).

354 ^1H NMR (CDCl_3 , 400 MHz) δ 1.35 (s, 3H), 1.52 (s, 3H), 1.61 (d, J = 3.6 Hz, 1H),
355 2.04–2.08 (m, 1H), 2.44 (q, J = 2.0 Hz, 1H), 3.62 (td, J = 8.4, 2.4 Hz, 1H), 3.82–3.87
356 (m, 2H), 3.96–4.01 (m, 1H), 4.09 (dd, J = 7.2, 5.6 Hz, 1H), 4.15 (dd, J = 5.2, 2.0 Hz,

357 1H), 4.29 (d, $J = 8.4$ Hz, 1H), 4.66 (d, $J = 12.0$ Hz, 1H), 4.92 (d, $J = 12.0$ Hz, 1H),
358 7.30–7.38 (m, 5H).
359 ^{13}C NMR (CDCl_3 , 100 MHz) δ 26.3, 28.1, 62.4, 71.3, 73.5, 73.6, 73.9, 78.8, 101.2,
360 110.4, 128.1, 128.2, 128.5, 136.8

361

362 (2*R*,3*R*,4*S*,5*R*)-5,6-Bis(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2*H*-pyran-3,4-d
363 iol



364

11a


365 A stirred suspension of **10a** (1.24 g, 4.0 mmol) in dry DMF (10 mL) was added
366 NaH (60% in mineral oil, 400 mg, 10.0 mmol, 2.5 equiv.) in 2 portions at 0 °C, and
367 stirred for 2 h, followed by treatment of benzyl bromide (1.2 mL, 10.0 mmol, 2.5
368 equiv.), stirred for 8 h at RT, MeOH (1.5 equiv.) was added to quench the reaction
369 slowly until no gas was formed. After extracted 2 times with EtOAc/H₂O (1:1, 10 mL),
370 the organic layer was concentrated *in vacuo*. Aqueous acetic acid (60%) was added
371 to the crude residue, stirred at 65°C for 2 h. Most solvent was removed in *vacuo*
372 before NaHCO₃ and MeOH was added to neutralize the residual HOAc. The
373 mixture was stirred for 30 min and then concentrated in *vacuo* to afford a crude
374 viscous, followed by column chromatography (hexane/EtOAc = 1:1), yielded **11a**
375 (990 mg, 2.2 mmol, 55% yield) as a white solid.

376 ^1H NMR (CDCl_3 , 400 MHz) δ 2.47 (d, $J = 2.8$ Hz, 1H), 2.57 (d, $J = 2.8$ Hz, 1H), 3.55–
377 3.59 (m, 2H), 3.63 (t, $J = 5.6$ Hz, 1H), 3.76–3.84 (m, 2H), 4.01 (s, 1H), 4.48 (d, $J =$
378 7.6 Hz, 1H), 4.61 (s, 2H), 4.66 (d, $J = 11.6$ Hz, 2H), 4.98 (dd, $J = 11.6, 4.0$ Hz, 2H),
379 7.29–7.39 (m, 15H).

380 ^{13}C NMR (CDCl_3 , 100 MHz) δ 68.9, 69.3, 70.9, 73.1, 73.3, 73.7, 74.6, 79.1, 102.4,
381 127.6(9), 127.7(4), 127.8, 127.8(5), 127.9(1), 128.1, 128.4, 128.4, 128.5, 137.3,
382 137.8, 138.2.

383

384 (2*R*,3*S*,4*S*,5*R*)-5,6-Bis(benzyloxy)-2-((benzyloxy)methyl)-4-((4-methoxybenzyl)oxy)
385 tetrahydro-2*H*-pyran-3-ol



386 **12a**

386


387 A mixture of **11a** (900 mg, 2.0 mmol) and dibutyltin oxide (600 mg, 2.4 mmol, 1.2
388 equiv.) in methanol (10 mL) was refluxed for 10 h with stirring. The solvent was
389 removed and dried in *vacuo*. To the residue in dry benzene (10 mL) was added
390 *para*-methoxy benzyl chloride (PMB-Cl: 540 μ L, 4.0 mmol, 2.0 equiv.), MS4Å (0.4 g)
391 and tetrabutylammonium bromide (TBAB: 322 mg, 1.0 mmol, 0.5 equiv.), refluxed
392 for 6 h. The mixture was concentrated in *vacuo*, followed by column chromatography
393 (hexane/EtOAc = 3:1), yielded **12a** as a viscous oil liquid (1.01 g, 1.8 mmol, 89%
394 yield).

395 ^1H NMR (CDCl_3 , 400 MHz) δ 3.47 (dd, $J = 9.6, 3.2$ Hz, 1H), 3.57 (q, $J = 5.2$ Hz, 1H),
396 3.69 (dd, $J = 9.6, 8.0$ Hz, 1H), 3.76–3.84 (m, 5H), 4.00 (s, 1H), 4.46–4.47 (m, 1H),
397 4.61–4.74 (m, 7H), 4.90–5.00 (m, 2H), 6.84 (dd, $J = 6.8, 2.0$ Hz, 2H), 7.24–7.38 (m,
398 17H).

399 ^{13}C NMR (CDCl_3 , 100 MHz) δ 55.2, 68.9, 70.9, 72.7, 73.5, 74.4, 75.2, 79.6, 82.0,
400 102.8, 113.7, 127.4(7), 127.5(2), 127.6, 127.8, 127.9, 128.1, 128.2, 128.3, 128.3(5),
401 128.4(1), 129.2, 130.6, 137.6, 137.9, 138.6, 138.7, 159.1.

402

403 (3*R*,4*S*,5*R*,6*R*)-2,3,5-Tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2*H*-pyran-4-
404 ol



GA3

405

406 A stirred suspension of **12a** (620 mg, 2.0 mmol) in dry DMF (5 mL) was added NaH
 407 (60% in mineral oil, 200 mg, 5.0 mmol, 2.5 equiv.) in 2 portions at 0 °C, and stirred
 408 for 2 h, followed by treatment of benzyl bromide (600 μ L, 5.0 mmol, 2.5 equiv.),
 409 stirred for 8 h at RT, MeOH (1.5 equiv.) was added to quench the reaction slowly
 410 until no gas was formed and organic solvent was removed in *vacuo*. The mixture
 411 was dissolved in CH₂Cl₂ and washed with 2M HCl and then with saturated NaHCO₃
 412 solution, dried over Na₂SO₄ and then concentrated. Water (1 mL) was added to the
 413 resultant mixture in CH₂Cl₂ (15 mL) followed by addition of
 414 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ: 680 mg, 3.0 mmol 1.5 equiv.) under
 415 stirring. The mixture was stirred for 1 h at room temperature and the completion of
 416 the reaction was monitored by TLC. CH₂Cl₂ was filtered and the residue was
 417 repeatedly washed with CH₂Cl₂. Filtrates were collected, washed with NaHCO₃
 418 solution, dried over Na₂SO₄ and then concentrated. The residue was subjected to
 419 silica gel column chromatography (hexane/EtOAc = 5:1), yielded **GA3** as an oil
 420 liquid (775 mg, 1.4 mmol, 72% yield).

421 ¹H NMR (CDCl₃, 400 MHz) δ 2.26 (d, *J* = 3.2 Hz, 1H), 3.60–3.67 (m, 5H), 3.87 (s,
 422 1H), 4.44–4.53 (m, 3H), 4.62–4.69 (m, 3H), 4.79 (d, *J* = 11.6 Hz, 1H), 4.96 (q, *J* =
 423 6.0 Hz, 2H), 7.29–7.37 (m, 20H).


424 ¹³C NMR (CDCl₃, 100 MHz) δ 68.7, 70.8, 73.5, 73.6, 74.0, 74.6, 74.9, 75.4, 79.6,
 425 102.5, 127.6, 127.7, 127.8, 128.1, 128.2(5), 128.2(8), 128.4, 137.4, 137.8, 138.3,
 426 138.4

427

428

429 **Preparation of glycosyl donor GA4** (Fig. S5)

430 (3*R*,4*S*,5*R*)-2-(Benzyloxy)tetrahydro-2*H*-pyran-3,4,5-triol



431 **9b**


432 To a stirred solution of D-xylose [ref. S2] (3.0 g, 20.0 mmol) in DMF (30 mL), a
 433 60% dispersion of NaH in mineral oil (800 mg, 20.0 mmol, 1.0 equiv.) was added in
 434 3 portions at 0°C. After stirring the mixture for 30 min, benzyl bromide (BnBr: 280
 435 μL , 2.4 mmol, 1.2 equiv.) was added to the resultant mixture, stirred for a further 3 h
 436 at RT; MeOH (1.2 equiv.) was then added to stop the reaction. The reaction mixture
 437 was concentrated in *vacuo*, followed by flash column chromatography
 438 (EtOAc/MeOH = 4:1) to yield **9b** as an amorphous white solid (2.16 g, 9.0 mmol,
 439 45% yield).

440 ^1H NMR (CDCl_3 , 400 MHz) δ 2.10 (s, 1H), 3.18–3.23 (m, 1H), 3.39–3.46 (m, 1H),
 441 3.58–3.69 (m, 1H), 3.84–3.99 (m, 1H), 4.33–4.37 (m, 1H), 4.45 (d, $J = 12.0$ Hz, 1H),
 442 4.54 (d, $J = 12.0$ Hz, 1H), 4.71 (d, $J = 12.0$ Hz, 1H), 4.83 (d, $J = 12.0$ Hz, 1H), 5.30
 443 (s, 1H), 7.27–7.33 (m, 5H).

444 ^{13}C NMR (CDCl_3 , 100 MHz) δ 61.7, 65.2, 69.1, 69.5, 69.8, 70.9, 71.8, 73.0, 74.3,
 445 76.0, 97.5, 102.1, 127.9, 128.0, 128.1, 128.4, 136.9.

446

447 (2*R*,3*R*,4*aR*,8*R*,8*aR*)-7-(Benzyloxy)-2,3-dimethoxy-2,3-dimethylhexahydro-5*H*-pyra
 448 no[3,4-*b*][1,4]dioxin-8-ol



449 **10b**

450 To a solution of **9b** [ref. S6] (1.92 g, 8.0 mmol) in MeOH (30 mL), trimethyl
 451 orthoformate (4.4 mL, 40.0 mmol, 5.0 equiv.), 2,3-butanedione (1 mL, 12.0 mmol,
 452 1.5 equiv.), and (\pm)-CSA (200 mg) were added and the mixture was refluxed for 20
 453 h under an argon atmosphere, cooled to room temperature and neutralized by the
 454 addition of triethylamine (1 mL). Solvents were evaporated under reduced pressure
 455 and the residue was purified by silica gel column chromatography (hexane/EtOAc =


456 3:1) to afford **10b** as a white solid (1.06 g, 3.0 mmol, 38% yield).

457 ¹H NMR (CDCl₃, 400 MHz) δ 1.30 (s, 3H), 1.35 (s, 3H), 3.27 (s, 3H), 3.30 (s, 3H),
458 3.43 (t, *J* = 9.8 Hz, 1H), 3.57–3.67 (m, 2H), 3.78–3.84 (m, 1H), 3.93 (q, *J* = 5.2 Hz,
459 1H), 4.36 (d, *J* = 9.8 Hz, 1H), 4.60 (d, *J* = 7.6 Hz, 1H), 4.90 (d, *J* = 7.6 Hz, 1H), 7.31–
460 7.37 (m, 5H).

461 ¹³C NMR (CDCl₃, 100 MHz) δ 17.5, 17.6, 47.9, 64.1, 65.8, 71.1, 71.3, 72.2, 99.4,
462 99.7, 103.2, 128.0, 128.2, 128.5, 136.8.

463

464 (3*R*,4*S*,5*R*)-5-(Allyloxy)-6-(benzyloxy)tetrahydro-2*H*-pyran-3,4-diol



465


466 To a stirred solution of **10b** (1.0 g, 2.8 mmol) in DMF (5 mL), a 60% dispersion of
467 NaH in mineral oil (110 mg, 2.8 mmol, 1.0 equiv.) was added in 3 portions at 0°C.
468 After stirring the mixture for 30 min, allyl bromide (250 μL, 3.0 mmol, 1.1 equiv.) was
469 added to the resultant mixture, stirred for a further 3 h at RT; MeOH (1.0 equiv.) was
470 then added to stop the reaction. The reaction mixture was concentrated in *vacuo*.
471 To a solution of the residue in dichloromethane (10 mL) was added 95% aqueous
472 trifluoroacetic acid (5 mL) and the whole mixture was stirred for 15 min. Solvents
473 were evaporated in *vacuo* and the residue was immediately purified by column
474 chromatography (hexane/EtOAc = 1:1) to afford **11b** as a white solid (196 mg, 0.70
475 mmol, 25% yield).

476 ¹H NMR (CDCl₃, 400 MHz) δ 3.35 (dd, *J* = 6.8, 4.8 Hz, 1H), 3.49 (dd, *J* = 12.0, 6.4
477 Hz, 1H), 3.71 (dd, *J* = 10.4, 4.8 Hz, 2H), 4.08–4.16 (m, 2H), 4.27 (dd, *J* = 12.8, 5.6
478 Hz, 1H), 4.59 (d, *J* = 11.6 Hz, 1H), 4.69 (d, *J* = 4.4 Hz, 1H), 4.86 (d, *J* = 12.0 Hz, 1H),
479 5.19–5.29 (m, 2H), 5.84–5.94 (m, 1H), 7.30–7.39 (m, 5H).

480 ¹³C NMR (CDCl₃, 100 MHz) δ 63.3, 69.2, 70.4, 72.5, 77.9, 100.3, 118.0, 127.9,
481 128.0, 128.1, 128.5, 134.0, 136.7

482

483 (3*R*,4*S*,5*R*)-3-(Allyloxy)-2,4,5-tris(benzyloxy)tetrahydro-2*H*-pyran



484


485 To a stirred solution of **11b** (168 mg, 0.60 mmol) in DMF (5 mL), a 60%
486 dispersion of NaH in mineral oil (60.0 mg, 1.5 mmol, 2.5 equiv.) was added at 0°C.
487 After stirring the mixture for 30 min, benzyl bromide (BnBr: 180 μ L, 1.5 mmol, 2.5
488 equiv.) was added to the resultant mixture, stirred for a further 3 h at RT; MeOH (1.2
489 equiv.) was then added to stop the reaction. The reaction mixture was concentrated
490 in *vacuo*, followed by flash column chromatography (EtOAc/MeOH = 5:1) to yield
491 **12b** as a viscous oil liquid (215 mg, 0.47 mmol, 78% yield).

492 ^1H NMR (CDCl_3 , 400 MHz) δ 3.20 (dd, $J = 11.6, 6.0$ Hz, 1H), 3.05 (dd, $J = 9.2, 8.0$
493 Hz, 1H), 3.52 (t, $J = 9.2$ Hz, 1H), 3.57–3.63 (m, 1H), 3.94 (dd, $J = 11.6, 5.2$ Hz, 1H),
494 4.18–4.23 (m, 1H), 4.40 (d, $J = 7.6$ Hz, 2H), 4.62 (d, $J = 12.0$ Hz, 2H), 4.74 (d, $J =$
495 11.6 Hz, 1H), 4.81–4.93 (m, 3H), 5.16 (dt, $J = 10.4$ Hz, 1.2 Hz, 1H), 5.26 (dt, $J =$
496 17.2 Hz, 2.4 Hz, 1H), 5.89–5.97 (m, 1H), 7.28–7.38 (m, 15H).

497 ^{13}C NMR (CDCl_3 , 100 MHz) δ 63.9, 71.0, 73.4, 73.8, 75.6, 77.7, 81.5, 83.7, 103.1,
498 116.9, 127.6, 127.7, 127.8, 128.0, 128.3, 128.3(6), 128.4(1), 135.0, 137.4, 138.2,
499 138.6.

500

501 (3*R*,4*R*,5*R*)-2,4,5-Tris(benzyloxy)tetrahydro-2*H*-pyran-3-ol



502

503 A mixture of **12b** (184 mg, 0.40 mmol), sodium acetate (82.0 mg, 1.0 mmol, 2.5
504 equiv.), PdCl_2 (85.0 mg, 0.48 mmol, 1.2 equiv.), and aqueous acetic acid (acetic
505 acid/ $\text{H}_2\text{O} = 11:1$, 6 mL) was stirred at RT for 48 h. After removing acetic acid and
506 water in *vacuo*, the residue was subjected to silica gel column chromatography

507 (hexane/EtOAc = 3:1) to afford **GA4** as a white amorphous solid (138 mg, 0.33
508 mmol, 82% yield).

509 ¹H NMR (CDCl₃, 400 MHz) δ 2.74 (s, 1H), 3.35 (dd, *J* = 12.0, 8.0 Hz, 1H), 3.55–3.63
510 (m, 4H), 4.03 (dd, *J* = 11.6, 3.6 Hz, 1H), 4.46 (d, *J* = 6.0 Hz, 1H), 4.60–4.71 (m, 3H),
511 4.80–4.89 (m, 3H), 7.28–7.35 (m, 15H).

512 ¹³C NMR (CDCl₃, 100 MHz) δ 62.4, 70.5, 72.1, 72.8, 74.1, 80.9, 101.6, 127.6, 127.8,
513 127.9, 128.3(5), 128.4(0), 128.5, 137.2, 137.8, 138.4.

514

515

516 **Typical procedure of glycosylation of GD and GA followed by deprotection for**
517 **G1-G8 and G10** (Fig. S6)

518

519 **Glycosylation**

520 A 20 mL oven-dried Schlenk tube was charged with thioglycoside **GD1** (25.0 mg,
521 0.04 mmol) and glycosyl acceptor **GA1** (23.0 mg, 1.0 equiv.) and dry CH₂Cl₂ (2 mL).
522 The mixed solution was cooled down to –40 °C, N-iodosuccinimide (NIS; 18.0 mg,
523 0.08 mmol, 2.0 equiv.) was added until totally dissolved, followed by 2 μL of TfOH.
524 The reaction mixture was allowed to warm to RT slowly. After that, it was cooled to
525 0 °C before triethylamine was added to neutralize the mixture. The mixture was
526 concentrated *in vacuo* and purified by column chromatography (hexane/EtOAc =
527 5:1) to yield the mixture of two anomers (28.1 mg, 0.03 mmol, 70% yield). After TLC
528 isolation with CHCl₃/MeOH (40:1), the pure form of the β anomer (**G1'**, precursor of
529 **G1**) was isolated as the minor product, along with α anomer (**G2'**, precursor of **G2**)
530 as the major one.

531

532 **Deprotection**

533

534 A 20 mL Schlenk tube was charged with isolated **G1'** (7.0 mg) in MeOH/EtOAc
535 (1:1 v/v, 2 mL) under N₂, then added Pd(OH)₂/C (10%) (7.0 mg), H₂ gas was later
536 charged and replace the N₂ by air pump vacuum/H₂ exchange, the reaction mixture

537 was stirred at room temperature for overnight, the completion of the reaction was
538 monitored by LC-MS. The mixture was subjected to filtration by passing through a
539 packed Celite® cake, to remove Pd(OH)₂/C, the crude residue was obtained after
540 removing the solvent *in vacuo*, followed by reverse phase TLC (H₂O), afforded the
541 corresponding product **G1** as a white solid (2.5 mg, 95%). In the same procedure,
542 the reaction of **G2'** (α anomer of **G1'**, 7.0 mg) yielded **G2** as white solid (2.5 mg,
543 95%).

544 The NMR spectra of isolated disaccharide in D₂O was difficult to identify each
545 signal to corresponding proton, nevertheless, the absence of aromatic proton in
546 ¹H-NMR spectra was obviously observed which helped us to confirm the completion
547 of the removal of all benzyl groups. The formation of desired disaccharide **G** was
548 confirmed via HRMS showing the consistence of the found value with exact mass
549 calculated.


550

551 Other disaccharides **G3–G8** and **G10** were synthesized in the same procedure
552 through a glycosylation of corresponding **GD** and **GA**, followed by a hydrogenative
553 deprotection.

554 The yield and additional information of each disaccharide was listed in Fig. S6.

555

556 Benzyl(2*S*,3*S*,4*S*,5*R*,6*R*)-4,5-bis(benzyloxy)-3-methoxy-6-(((2*R*,3*S*,4*S*,5*R*)-3,4,5,6-
557 tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carbo-
558 xylate



559

G1'


560 Glycosylation of **GD1** and **GA1** (β)

561 ¹H NMR (CDCl₃, 600 MHz) δ 3.31 (s, 3H), 3.46 (t, *J* = 6.4 Hz, 1H), 3.50–3.51 (m,

562 2H), 3.67–3.70 (m, 1H), 3.75–3.78 (m, 2H), 3.98–4.02 (m, 2H), 4.09–4.11 (m, 1H),
 563 4.35 (t, $J = 7.2$ Hz, 1H), 4.40 (d, $J = 7.2$ Hz, 1H), 4.45 (dd, $J = 2.0, 12.8$ Hz, 2H),
 564 4.53–4.58 (m, 3H), 4.65–4.75 (m, 5H), 4.83 (d, $J = 11.0$ Hz, 1H), 4.88–5.02 (m, 2H),
 565 5.14 (d, $J = 8.0$ Hz, 1H), 5.17 (d, $J = 8.1$ Hz, 1H), 7.19–7.29 (m, 35H).
 566 ^{13}C NMR (CDCl_3 , 150 MHz) δ 60.5, 67.1, 68.5, 69.9, 72.1, 72.3, 73.1, 74.3, 74.7,
 567 75.5, 79.2, 80.1, 80.6, 81.1, 81.4, 83.6, 83.9, 98.1, 103.9, 127.3, 127.5, 127.6,
 568 127.7, 127.8, 127.9, 128.2, 128.3, 128.4, 135.1, 137.4, 138.0, 138.1, 138.3, 138.4,
 569 168.4.

570

571 (2*S*,3*S*,4*R*,5*R*,6*R*)-4,5-Dihydroxy-3-methoxy-6-(((2*R*,3*R*,4*S*,5*R*)-3,4,5,6-tetrahydrox
 572 ytetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carboxylic acid




573

G1 4-Me-GlcA- β (1,6)Gal

574 HRMS (ESI) m/z calcd for $\text{C}_{13}\text{H}_{21}\text{O}_{12}$ [$\text{M}-\text{H}$] $^-$: 369.1028, found: 369.1022.

575

576 Benzyl(2*S*,3*S*,4*S*,5*R*,6*S*)-4,5-bis(benzyloxy)-3-methoxy-6-(((2*R*,3*S*,4*S*,5*R*)-3,4,5,6-t
 577 etrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carbox
 578 ylate



579

G2'


580 Glycosylation of **GD1+GA1** (α)

581 ^1H NMR (CDCl_3 , 600 MHz) δ 3.33 (s, 3H), 3.37–3.41 (m, 2H), 3.50 (dd, $J = 9.6, 3.4$

582 Hz, 1H), 3.70 (dd, $J = 9.6, 6.9$ Hz, 1H), 3.85–3.88 (m, 2H), 3.98–4.00 (m, 4H), 4.34
 583 (d, $J = 6.9$ Hz, 1H), 4.51–4.57 (m, 2H), 4.65–4.76 (m, 6H), 4.83–4.87 (m, 3H), 4.91
 584 (d, $J = 11.7$ Hz, 2H), 5.17 (d, $J = 12.4$ Hz, 1H), 5.23 (d, $J = 12.4$ Hz, 2H) 7.24–7.41
 585 (m, 35H)
 586 ^{13}C NMR (CDCl_3 , 150 MHz) δ 60.6, 67.1, 68.0, 68.9, 69.5, 70.3, 73.0, 73.4, 73.5,
 587 74.5, 75.3, 75.7, 76.4, 79.0, 79.1, 81.3, 81.8, 95.6, 97.7, 127.50, 127.55, 127.63,
 588 127.69, 127.77, 127.86, 127.9, 128.1, 128.21, 128.26, 128.34, 128.4, 128.5, 135.2,
 589 137.3, 138.0, 138.45, 138.5, 138.8, 169.8.

590

591 (2*S*,3*S*,4*R*,5*R*,6*S*)-4,5-Dihydroxy-3-methoxy-6-(((2*R*,3*R*,4*S*,5*R*)-3,4,5,6-tetrahydrox
 592 ytetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carboxylic acid




593 **G2** 4-Me-GlcA- α (1,6)Gal

594 HRMS (ESI) m/z calcd for $\text{C}_{13}\text{H}_{21}\text{O}_{12}$ $[\text{M}-\text{H}]^-$: 369.1028, found: 369.1037.

595

596 Benzyl(2*S*,3*S*,4*S*,5*R*,6*R*)-4,5-bis(benzyloxy)-3-methoxy-6-(((2*R*,3*R*,4*S*,5*R*)-3,4,5,6-
 597 tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carbo
 598 xylate



599

G3'

600 Glycosylation of **GD1+GA2** (β)


601 ^1H NMR (CDCl_3 , 400 MHz) δ 3.34 (s, 3H), 3.38–3.41 (m, 1H), 3.45–3.52 (m, 4H),

602 3.58 (t, $J = 6.0$ Hz, 1H), 3.62–3.68 (m, 1H), 3.76–3.79 (m, 1H), 4.02–4.09 (m, 1H),
603 4.36 (q, $J = 4.8$ Hz, 1H), 4.24–4.44 (m, 1H), 4.47–4.53 (m, 3H), 4.62–4.64 (m, 1H),
604 4.68–4.79 (m, 4H), 4.81–4.85 (m, 2H), 4.91–4.99 (m, 3H), 5.20–5.24 (m, 2H), 7.15–
605 7.39 (m, 35H).

606 ^{13}C NMR (CDCl_3 , 100 MHz) δ 60.7, 67.3, 68.8, 68.9, 70.2, 71.2, 73.0, 74.5, 74.6,
607 75.0, 75.0(5), 75.1(3), 75.8, 78.0, 78.3, 79.9, 81.1(6), 81.2(3), 81.4, 81.5, 82.0, 82.3,
608 83.9, 84.0, 84.7, 95.2, 102.7, 104.1, 104.2, 127.6, 127.7, 127.7(8), 127.8(2), 127.9,
609 128.0, 128.1, 128.2, 128.3, 128.4, 128.5(0), 128.5(4), 128.5(8), 128.6(0), 128.6(3),
610 128.7, 128.8, 129.0, 135.3, 137.2, 137.6, 138.0, 138.2, 138.3, 138.3(6), 138.4(2),
611 138.6, 139.0, 168.4, 168.6.

612

613 (2*S*,3*S*,4*R*,5*R*,6*R*)-4,5-Dihydroxy-3-methoxy-6-(((2*R*,3*S*,4*S*,5*R*)-3,4,5,6-tetrahydrox
614 ytetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carboxylic acid




615 **G3** 4-Me-GlcA- β (1,6)Glc

616 HRMS (ESI) m/z calcd for $\text{C}_{13}\text{H}_{22}\text{O}_{12}\text{Na}$ $[\text{M}+\text{Na}]^+$: 393.1003, found: 393.0994.

617

618 Benzyl(2*S*,3*S*,4*S*,5*R*,6*R*)-4,5-bis(benzyloxy)-3-methoxy-6-(((3*R*,4*S*,5*S*,6*R*)-2,3,5-tri
619 s(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2*H*-pyran-4-yl)oxy)tetrahydro-2*H*-pyr
620 an-2-carboxylate



621

G4'

622 Glycosylation of **GD1+GA3** (β)


623 ^1H NMR (CDCl_3 , 400 MHz) δ 3.28 (s, 3H), 3.41 (t, $J = 9.6$ Hz, 1H), 3.47–3.60 (m,

624 5H), 3.67 (d, $J = 10.0$ Hz, 1H), 3.82–3.87 (m, 2H), 3.94 (t, $J = 9.6$ Hz, 1H), 4.36–
625 4.46 (m, 4H), 4.53–4.67 (m, 3H), 4.74–4.83 (m, 4H), 4.90 (t, $J = 12.4$ Hz, 2H), 4.99
626 (d, $J = 11.2$ Hz, 1H), 5.10–5.14 (m, 2H), 7.22–7.40 (m, 35H).

627 ^{13}C NMR (CDCl_3 , 100 MHz) δ 60.4, 66.8, 68.7, 70.5, 71.0, 73.3, 73.4, 74.2, 74.5,
628 74.7, 75.5, 79.2, 80.5, 81.2, 82.0, 97.1, 103.2, 127.2, 127.6, 127.7(5), 127.8(0),
629 127.9(0), 127.9(2), 128.0, 128.1, 128.2, 128.3, 128.3(7), 128.4(3), 135.3, 137.4,
630 137.7, 138.0, 138.3(7), 138.4(3), 169.9.

631

632 (2*S*,3*S*,4*R*,5*R*,6*R*)-4,5-Dihydroxy-3-methoxy-6-(((3*R*,4*S*,5*S*,6*R*)-2,3,5-trihydroxy-6-(
633 hydroxymethyl)tetrahydro-2*H*-pyran-4-yl)oxy)tetrahydro-2*H*-pyran-2-carboxylic acid




634

G4 4-Me-GlcA- β (1,3)Gal

635 HRMS (ESI) m/z calcd for $\text{C}_{13}\text{H}_{22}\text{O}_{12}\text{Na}$ $[\text{M}+\text{Na}]^+$: 393.1003, found: 393.1001.

636

637 Benzyl(2*S*,3*S*,4*S*,5*R*,6*R*)-4,5-bis(benzyloxy)-3-methoxy-6-(((3*R*,4*S*,5*R*)-2,4,5-tris(b
638 enzyloxy)tetrahydro-2*H*-pyran-3-yl)oxy)tetrahydro-2*H*-pyran-2-carboxylate



639

G5'

640 Glycosylation of **GD1+GA4** (β)


641 ^1H NMR (CDCl_3 , 400 MHz) δ 3.35 (s, 3H), 3.39–3.54 (m, 3H), 3.59–3.64 (m, 2H),
642 3.67–3.73 (m, 1H), 3.79–3.81 (m, 1H), 3.94–4.05 (m, 1H), 4.53–4.58 (m, 2H), 4.60–
643 4.65 (m, 2H), 4.74–4.84 (m, 5H), 4.87–4.91 (m, 1H), 5.15–5.28 (m, 3H), 7.22–7.41
644 (m, 30H).

645 ^{13}C NMR (CDCl_3 , 100 MHz) δ 60.5, 63.2, 67.1, 70.0, 72.9, 74.2, 74.9, 75.0, 75.5,

646 75.6, 77.9, 78.4, 81.1, 82.1, 83.4, 83.9, 101.4, 102.7, 127.4, 127.5, 127.6, 127.8(7),
647 127.9(1), 128.1(5), 128.2(2), 128.3, 128.4, 128.5, 128.6, 128.7, 137.7, 137.9, 138.3,
648 168.3.

649

650 (2*S*,3*S*,4*R*,5*R*,6*R*)-4,5-Dihydroxy-3-methoxy-6-(((3*R*,4*S*,5*R*)-2,4,5-trihydroxytetrahy
651 dro-2*H*-pyran-3-yl)oxy)tetrahydro-2*H*-pyran-2-carboxylic acid




652 **G5** 4-Me-GlcA- β (1,2)Xyl

653 HRMS (ESI) *m/z* calcd for C₁₂H₂₀O₁₁Na [M+Na]⁺: 363.0898, found: 363.0888.

654

655 Benzyl(2*S*,3*S*,4*S*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-(((2*R*,3*S*,4*S*,5*R*)-3,4,5,6-tetrakis(b
656 enzyloxy)tetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carboxylate



657

G6'


658 Glycosylation of **GD2+GA1** (β) C₆₈H₆₈O₁₂

659 ¹H NMR (CDCl₃, 400 MHz) δ 3.50 (t, *J* = 8.8 Hz, 1H), 3.61 (t, *J* = 8.8 Hz, 1H), 3.69
660 (dd, *J* = 8.4, 7.6 Hz, 1H), 3.79–3.88 (m, 3H), 3.98–4.04 (m, 2H), 4.11 (dd, *J* = 10.8,
661 2.4 Hz, 1H), 4.36 (t, *J* = 7.2 Hz, 1H), 4.42–4.48 (m, 4H), 4.53–4.59 (m, 3H), 4.66–
662 4.76 (m, 6H), 4.85–4.93 (m, 3H), 5.09 (s, 2H), 7.09–7.30 (m, 40H).

663 ¹³C NMR (CDCl₃, 100 MHz) δ 67.2, 68.6, 69.9, 72.2, 72.4, 73.1, 74.5, 74.8, 75.0,
664 75.7, 79.3, 80.1, 80.6, 81.6, 83.7, 84.0, 98.1, 104.0, 127.4, 127.6, 127.6(8), 127.7(4),
665 127.8, 128.0, 128.2, 128.3, 128.3(5), 128.3(9), 128.5, 135.0, 137.4(5), 137.5(3),
666 137.8, 138.1, 138.3, 138.4, 168.4.

667

668 (2*S*,3*S*,4*S*,5*R*,6*R*)-3,4,5-Trihydroxy-6-(((2*R*,3*R*,4*S*,5*R*)-3,4,5,6-tetrahydroxytetrahy
669 dro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carboxylic acid




670

G6 GlcA- β (1,6)-Gal

671 HRMS (ESI) *m/z* calcd for C₁₂H₂₀O₁₂Na [M+Na]⁺: 379.0847, found: 379.0864.

672

673 Benzyl(2*S*,3*S*,4*S*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-(((3*R*,4*S*,5*R*)-2,4,5-tris(benzyloxy)
674 tetrahydro-2*H*-pyran-3-yl)oxy)tetrahydro-2*H*-pyran-2-carboxylate



675

G7'


676 Glycosylation of **GD2+GA4** (β)

677 ¹H NMR (CDCl₃, 400 MHz) δ 3.18 (t, *J* = 10.0 Hz, 1H), 3.44 (dd, *J* = 10.0, 3.6 Hz,
678 1H), 3.56–3.66 (m, 3H), 3.73 (t, *J* = 8.0 Hz, 1H), 3.86–3.91 (m, 2H), 4.30 (t, *J* = 11.6
679 Hz, 2H), 4.39 (d, *J* = 11.6 Hz, 1H), 4.47–4.56 (m, 4H), 4.59–4.68 (m, 2H), 4.73–4.90
680 (m, 5H), 4.98 (d, *J* = 2.4 Hz, 2H), 5.62 (d, *J* = 3.2 Hz, 1H), 6.95–7.30 (m, 35H).

681 ¹³C NMR (CDCl₃, 100 MHz) δ 63.8, 66.8, 70.3, 70.7, 71.9, 73.2, 74.8, 75.2, 75.3,
682 75.7, 78.4, 78.9, 79.9, 80.8, 81.2, 95.4, 103.3, 127.2, 127.4, 127.5, 127.6, 127.7,
683 127.9, 128.0, 128.1, 128.2, 128.3, 128.3(5), 128.4(4), 128.7, 135.3, 137.1, 137.6,
684 137.9, 138.3, 138.5, 170.2.

685

686 (2*S*,3*S*,4*S*,5*R*,6*R*)-3,4,5-Trihydroxy-6-(((3*R*,4*S*,5*R*)-2,4,5-trihydroxytetrahydro-2*H*-p
687 yran-3-yl)oxy)tetrahydro-2*H*-pyran-2-carboxylic acid




688 **G7** GlcA- β (1,2)-Xyl

689 HRMS (ESI) m/z calcd for $C_{11}H_{18}O_{11}Na$ $[M+Na]^+$: 349.0741, found: 349.0734.

690

691 (3*R*,4*S*,5*S*,6*R*)-2,3,4,5-Tetrakis(benzyloxy)-6-((((2*R*,3*R*,4*S*,5*R*,6*R*)-3,4-bis(benzyloxy)-6-((benzyloxy)methyl)-5-methoxytetrahydro-2*H*-pyran-2-yl)oxy)methyl)tetrahydr
692
693 o-2*H*-pyran



694 **G8'**


695 Glycosylation of **GD3+GA1** (β)

696 1H NMR ($CDCl_3$, 400 MHz) δ 3.32 (d, $J = 6.0$ Hz, 2H), 3.42–3.52 (m, 5H), 3.68–3.71
697 (m, 1H), 3.80–3.89 (m, 2H), 4.01–4.07 (m, 3H), 4.15 (dd, $J = 7.2, 3.2$ Hz, 1H), 4.29
698 (d, $J = 12.0$ Hz, 1H), 4.38–4.43 (m, 2H), 4.46–4.53 (m, 4H), 4.58–4.65 (m, 2H),
699 4.67–4.78 (m, 4H), 4.86–4.94 (m, 3H), 5.14 (s, 1H), 7.20–7.35 (m, 35H).

700 ^{13}C NMR ($CDCl_3$, 100 MHz) δ 60.5, 68.4, 69.0, 70.3, 71.8, 72.0, 73.0, 73.3, 73.6,
701 75.4, 75.7, 79.2, 79.7, 80.7, 81.3, 81.8, 82.7, 88.3, 97.7, 105.0, 127.4(7), 127.5(2),
702 127.5(9), 127.6(3), 127.6(6), 127.7(4), 127.7(9), 127.8(4), 127.8(7), 127.9(3), 128.0,
703 128.2, 128.2(6), 128.3(2), 128.3(4), 128.4, 137.6, 137.7, 137.8, 138.0, 138.1.

704

705 (3*R*,4*S*,5*R*,6*R*)-6-((((2*R*,3*R*,4*R*,5*S*,6*R*)-3,4-Dihydroxy-6-(hydroxymethyl)-5-methoxy
706 tetrahydro-2*H*-pyran-2-yl)oxy)methyl)tetrahydro-2*H*-pyran-2,3,4,5-tetraol



707

G8 GlcA- β (1,6)-Gal

708

HRMS (ESI) m/z calcd for $C_{13}H_{24}O_{11}Na$ $[M+Na]^+$: 379.1211, found: 379.1205.


709

710

Benzyl(2*S*,3*S*,4*S*,5*R*,6*R*)-4,5-bis(benzyloxy)-3-methoxy-6-((tetrahydro-2*H*-pyran-2-

711

yl)methoxy)tetrahydro-2*H*-pyran-2-carboxylate



712

G10'

713

Glycosylation of **GD1+ROH** (tetrahydropyran-2-methanol) (β)

714

1H NMR ($CDCl_3$, 400 MHz) δ 1.49–1.84 (m, 6H), 3.35 (s, 3H), 3.59–3.43(m, 5H),

715

3.79–3.91 (m, 2H), 3.97–4.00 (m, 1H), 4.46 (dd, $J = 13.2, 7.6$ Hz, 1H), 4.66–4.76 (m,

716

2H), 4.85 (dd, $J = 10.8, 2.0$ Hz, 1H), 4.96 (dd, $J = 10.8, 4.0$ Hz, 1H), 5.20–5.30 (m,

717

3H), 7.29–7.40 (m, 15H).

718

^{13}C NMR ($CDCl_3$, 100 MHz) δ 23.21, 25.9, 28.1, 28.3, 60.6, 67.2, 68.2, 68.4, 73.4,

719

73.7, 74.4, 74.6, 74.8, 75.6, 76.2, 81.0, 81.3(8), 81.4(4), 83.7, 103.9, 104.4, 127.6,

720

127.9, 128.2, 128.3, 128.4, 128.5, 128.6, 129.0, 135.2, 138.4, 168.4, 168.5.


721

722

(2*S*,3*S*,4*R*,5*R*,6*R*)-4,5-Dihydroxy-3-methoxy-6-((tetrahydro-2*H*-pyran-2-yl)methoxy)

723

tetrahydro-2*H*-pyran-2-carboxylic acid



724 **G10** 4-Me-GlcA- β -Pyran

725 HRMS (ESI) m/z calcd for $C_{13}H_{22}O_8Na$ $[M+Na]^+$: 329.1207, found: 329.1198.


726

727 **Preparation of G9** (Fig. S7)

728 To a stirred solution of the **G1** (1.5 mg) in 3 mL of toluene/MeOH (1:2), TMSCHN₂
 729 (1.1–1.5 mmol) was added dropwise until yellow color persisted. The mixture was
 730 stirred for 30 min at RT and concentrated to give the corresponding methyl ester **G9**
 731 as white solid (1.6 mg, 95% yield).

732

733 Methyl(2*S*,3*S*,4*R*,5*R*,6*R*)-4,5-dihydroxy-3-methoxy-6-(((2*R*,3*R*,4*S*,5*R*)-3,4,5,6-tetra
 734 hydroxytetrahydro-2*H*-pyran-2-yl)methoxy)tetrahydro-2*H*-pyran-2-carboxylate



G9

735

736 HRMS (ESI) m/z calcd for $C_{14}H_{24}O_{12}Na$ $[M+Na]^+$: 407.1165, found: 407.1173.

737

738

739 **Preparation of G11** (Fig. S8)

740 (2*R*,4*aR*,6*R*,7*R*,8*R*,8*aS*)-6-Methoxy-2-phenylhexahydropyrano[3,2-*d*][1,3]dioxine-7,
 741 8-diol



2-OMe

742


743 A mixture of commercially purchased 1-OMe-Glc (β) (776 mg, 4.0 mmol),
744 benzaldehyde dimethyl acetal (1.8 mL, 12.0 mmol), and TsOH \cdot H₂O (189 mg, 1.0
745 mmol, 0.25 equiv.) was heated at 50 °C for 3 h. The solution was neutralized with
746 NaHCO₃, filtration and wash with MeOH. The filtrate was concentrated *in vacuo* and
747 the residue was purified by flash column chromatography (EtOAc) and
748 recrystallized from EtOAc/hexane (1:2) afforded an analytical sample of acetal
749 **2-OMe** as a white solid (761 mg, 2.7 mmol, 68% yield).

750 ¹H NMR (CDCl₃, 400 MHz) δ 2.56 (s, 1H), 2.70 (s, 1H), 3.45–3.57 (m, 3H), 3.59 (s,
751 3H), 3.77–3.86 (m, 2H), 4.33–4.39 (m, 2H), 5.55 (s, 1H), 7.37–7.41 (m, 3H), 7.49–
752 7.51 (m, 2H).

753 ¹³C NMR (CDCl₃, 100 MHz) δ 57.5, 66.4, 68.7, 73.2, 74.5, 80.6, 101.9, 104.1, 126.3,
754 128.4, 129.3.

755

756 (2*R*,3*R*,4*S*,5*R*,6*R*)-4,5-Bis(benzyloxy)-2-(hydroxymethyl)-6-methoxytetrahydro-2*H*-
757 pyran-3-ol



758

3-OMe

759 To a stirred suspension of acetal **2-OMe** (676 mg, 2.4 mmol) in dry DMF (12 mL)
760 was added NaH 60% in mineral oil (240 mg, 6.0 mmol, 2.5 equiv.) in 2 portions at
761 0 °C, and stirred for 1 h, followed by treated with benzyl bromide (BnBr: 720 μ L, 6.0
762 mmol), stirred for 8 h at room temperature, and MeOH (1.0 equiv.) was added
763 slowly until no gas was formed to quench the reaction. After extracted with
764 EtOAc/H₂O = 1:1 (2 times), organic layer was concentrated *in vacuo* to remove
765 solvents to give a crude oil mixture. To the CH₂Cl₂/MeOH solution of the yielded oil
766 mixture was added TsOH \cdot H₂O (10 mol%), and then the mixture was stirred at room
767 temperature for overnight. The solution was neutralized with NaHCO₃, and organic
768 solvent was concentrated *in vacuo* to afford a crude viscous liquid. Column
769 chromatography (hexane/EtOAc = 1:1) yielded dibenzyl **3-OMe** as a white solid


770 (664 mg, 1.8 mmol, 74% yield).

771 ^1H NMR (CDCl_3 , 400 MHz) δ 2.03 (t, J = 6.0 Hz, 1H), 2.70 (d, J = 2.4 Hz, 1H), 3.32–
772 3.37 (m, 1H), 3.39–3.47 (m, 2H), 3.54 (dd, J = 9.2, 2.0 Hz, 1H), 3.74–3.80 (m, 1H),
773 3.87–3.92 (m, 1H), 4.37 (d, J = 7.6 Hz, 1H), 4.69 (dd, J = 14.4, 11.2 Hz, 2H), 4.95
774 (dd, J = 17.6, 12.8 Hz, 2H), 7.29–7.39 (m, 10H).

775 ^{13}C NMR (CDCl_3 , 100 MHz) δ 57.3, 62.5, 70.3, 74.6, 74.8, 75.2, 81.9, 83.8, 104.9,
776 127.7, 127.9, 128.1, 128.4, 128.6, 138.3, 138.4.

777

778 (2*R*,3*R*,4*S*,5*R*,6*R*)-4,5-Bis(benzyloxy)-6-methoxy-2-((trityloxy)methyl)tetrahydro-2*H*
779 -pyran-3-ol



4-OMe

780


781 Triphenylmethyl chloride (1.1 g, 4.0 mmol, 2.5 equiv.) and
782 *N,N*-dimethyl-4-aminopyridine (DMAP: 20.0 mg, 0.16 mmol) were added to a stirred
783 solution of dibenzyl **3-OMe** (600 mg, 1.6 mmol) in dry pyridine (10 mL) and the
784 reaction mixture heated at 60 °C for overnight. The reaction mixture was quenched
785 with MeOH (5 mL) and concentrated *in vacuo*. The resulting syrup was purified by
786 short column chromatography (hexane/EtOAc = 1:1) to give the trityl ether **4-OMe**
787 (523 mg, 0.85 mmol, 53% yield) as a viscous oil liquid.

788 ^1H NMR (CDCl_3 , 400 MHz) δ 2.46 (s, 1H), 3.35–3.47 (m, 5H), 3.60–3.66 (m, 4H),
789 4.34 (d, J = 7.6 Hz, 1H), 4.73 (t, J = 10.8 Hz, 2H), 4.92 (t, J = 10.8 Hz, 2H), 7.20–
790 7.38 (m, 20H), 7.42–7.48 (m, 5H).

791 ^{13}C NMR (CDCl_3 , 100 MHz) δ 56.8, 64.0, 71.7, 73.9, 74.7, 75.4, 81.9, 84.1, 86.8,
792 104.6, 127.0, 127.6, 127.7(6), 127.8(3), 127.9(6), 128.0(4), 128.3, 128.5, 128.6,
793 138.5, 138.6, 143.7.

794

795 ((2*R*,3*R*,4*S*,5*R*,6*R*)-4,5-Bis(benzyloxy)-3,6-dimethoxytetrahydro-2*H*-pyran-2-yl)met
796 hanol



797 **5-OMe**


798 To a stirred solution of trityl ether **4-OMe** (493 mg, 0.8 mmol) in DMF (8 mL) was
799 added 60% NaH dispersion in mineral oil (48.0 mg, 1.2 mmol, 1.5 equiv.) at 0 °C,
800 after 30 min, iodomethane (MeI: 75 μ L, 1.2 mmol) was added and the reaction
801 mixture was stirred for another 3 h at room temperature before 1.0 equiv. MeOH
802 was added to stop the reaction. The reaction mixture was extracted with
803 H₂O/EtOAc/hexane = 2:1:1 (10 mL) for 2 times to remove DMF, dried over Na₂SO₄.
804 After filtration, the mixture was concentrated *in vacuo*. The yielded crude product
805 was dissolved in MeOH/CH₂Cl₂ (30 mL) to afford a yellow solution which was
806 treated with TsOH·H₂O (10 mol%) and stirred at RT, after 6 h, NaHCO₃ was added
807 to neutralize the reaction. The yellow solution was concentrated *in vacuo*, followed
808 by a flash column chromatography (hexane/EtOAc = 3:1) to yield alcohol **5-OMe** as
809 a white solid (168 mg, 0.43 mmol, 54%).

810 ¹H NMR (CDCl₃, 400 MHz) δ 2.03 (t, *J* = 6.4 Hz, 1H), 3.28–3.31 (m, 2H), 3.35 (t, *J* =
811 8.4 Hz, 1H), 3.56 (s, 3H), 3.57 (s, 3H), 2.03 (t, *J* = 6.4 Hz, 1H), 3.74 (dd, *J* = 9.2, 7.2
812 Hz, 1H), 3.90 (dd, *J* = 12.0, 3.6 Hz, 1H), 4.34 (d, *J* = 8.0 Hz, 1H), 4.70 (d, *J* = 11.2
813 Hz, 1H), 4.79 (d, *J* = 11.2 Hz, 1H), 4.89 (d, *J* = 11.2 Hz, 2H), 7.27–7.35 (m, 10H).

814 ¹³C NMR (CDCl₃, 100 MHz) δ 57.2, 60.8, 61.9, 74.8, 75.0, 75.5, 79.5, 82.1, 84.2,
815 104.7, 127.6, 127.9, 128.0, 128.3, 138.4, 138.5

816

817 (2*S*,3*S*,4*S*,5*R*,6*R*)-4,5-Bis(benzyloxy)-3,6-dimethoxytetrahydro-2*H*-pyran-2-carbox
818 ylic acid



819 **6-OMe**


820 To a 10 mL CH₂Cl₂ solution of alcohol **5-OMe** (116 mg, 0.30 mmol) and buffer
 821 (Na₂HPO₄/NaH₂PO₄, PH=7) was added iodobenzene diacetate (193 mg, 0.60 mmol,
 822 2.0 equiv.) at 0 °C, followed by addition of 2-azaadamantane *N*-oxyl (AZADO, 4.0
 823 mg, 0.03 mmol, 0.1 equiv.). The mixture was stirred at the same temperature. The
 824 reaction was monitored by TLC, after 2 h, **5-OMe** was consumed, the reaction
 825 mixture was extracted by CH₂Cl₂ and water for 3 times, the organic layer was dried
 826 over Na₂SO₄, solvent was removed in *vacuo* and the residue was purified by a silica
 827 gel column chromatography (hexane/EtOAc = 5:1) to yield benzyl ether **6-OMe** as
 828 an amorphous solid (64.3 mg, 0.16 mmol, 53% yield).

829 ¹H NMR (CDCl₃, 400 MHz) δ 3.38–3.56 (m, 9H), 3.75 (s, 1H), 4.30 (d, *J* = 5.6 Hz,
 830 1H), 4.57 (d, *J* = 11.2 Hz, 1H), 4.75–4.80 (m, 4H), 7.22–7.23 (m, 10H).

831 ¹³C NMR (CDCl₃, 100 MHz) δ 57.8, 60.4, 74.6, 75.4, 81.8, 82.2, 83.6, 104.5, 127.4,
 832 127.7, 128.2, 138.4, 138.5, 174.2.

833

834 (2*S*,3*S*,4*R*,5*R*,6*R*)-4,5-Dihydroxy-3,6-dimethoxytetrahydro-2*H*-pyran-2-carboxylic
 835 acid



836 **G11**

837 A 20 mL Schlenk tube was charged with **6-OMe** (40.2 mg, 0.10 mmol) in
 838 MeOH/EtOAc = 1:1 solution (5 mL) under N₂, then added pre-activated
 839 (water-removed) Pd(OH)₂/C 20.0 mg, H₂ gas was later charged and replace the N₂
 840 by air pump vacuum/H₂ exchange, the reaction mixture was stirred at room
 841 temperature for overnight, the completion of the reaction was monitored by LC-MS.
 842 The mixture was subjected to filtration by passing through a packed Celite® cake,

843 to remove Pd(OH)₂/C, the residue was obtained after removing the solvent *in vacuo*,
844 followed by reverse phase TLC (MeOH), afford the corresponding product **G11** as
845 an off-white solid (22.2 mg, 0.10 mmol, quant.).

846 ¹H NMR (CD₃OD, 400 MHz) δ 3.13–3.21 (m, 1H), 3.24–3.25 (m, 2H), 3.40 (t, *J* = 9.2
847 Hz, 1H), 3.44 (s, 3H), 3.45 (s, 3H), 3.69 (d, *J* = 10.0 Hz, 1H), 4.14 (d, *J* = 8.0 Hz,
848 1H).

849 ¹³C NMR (CD₃OD 100 MHz) δ 57.6, 60.8, 74.8, 75.8, 77.3, 83.0, 105.5 (carbon
850 signal of C=O is missing for its low concentration in CD₃OD).

851 ¹³C NMR (D₂O 100 MHz) δ 57.6 (the standard peak based on that observed in
852 CD₃OD), 60.3, 72.9, 73.9, 75.1, 81.7, 103.4, 171.4.

853 HRMS (ESI) *m/z* calcd for C₈H₁₄O₇Na [M+Na]⁺: 245.0632 found: 245.0628.

854
855

856 **References:**

857 S1. A.G. Mizukami, R. Inatsugi, J. Jiao *et al. Curr. Bio.*, **2016**, *26*, 321–323;

858 S2. Ewing, David F. *et al. Carbohydrate Lett.*, **1997**, *2*, 273–280;

859 S3. a) J. Xia, J. L. Alderfer, *et al. Chem. Eur. J.*, **2001**, *7*, 356–367; b) S. Manner, U.
860 Ellervik, *Synlett*, **2014**, *25*, 1271–1274;

861 S4. M. Numata, M. Sugimoto, K. Koike, T. Ogawa, *Carbohydrate Res.*, **1987**, *163*,
862 209–225;

863 S5. U. S. Chowdhury, *Syn. Commun.*, **2000**, *30*, 3785–3792;

864 S6. P. Cmoch, Z. Pakulski *et al. Tetrahedron: Asymmetry*, **2008**, *19*, 1494–1503

865

866

867

868

869

870

871

872

873

Biology

874 **Table S2.** AMOR activity results for synthetic AMOR and derivatives.

875

Compound	Concentration (μM)	Responsive Pollen Tubes (%)	S.D.	S.E.	P value (Scheffé test) Comparison with 4-Me-GlcA- β (1,6)-Gal (G1)
4-Me-GlcA- β (1,6)-Gal G1	1.35	80.0	10.0	5.780	
4-Me-GlcA- α (1,6)-Gal G2	1.35	33.3	5.68	3.286	0.0054475 (**P<0.01)
4-Me-GlcA- β (1,6)-Glc G3	1.35	56.7	15.2	8.829	0.4897411 (insignificant)
4-Me-GlcA- β (1,3)-Gal G4	1.35	40.0	10.0	5.78	0.0241134 (*P<0.05)
4-Me-GlcA- β (1,2)-Xyl G5	1.35	26.7	11.5	6.674	0.0011994 (**P<0.01)
GlcA- β (1,6)-Gal G6	1.35	3.3	5.8	3.337	7.87E-06 (**P<0.01)
GlcA- β (1,2)-Xyl G7	1.35	6.7	5.8	3.337	6.28E-05 (**P<0.01)
4-Me-Glc- β (1,6)-Gal G8	1.35	13.33	11.5	6.674	4.05E-06 (**P<0.01)
4,6-Me-GlcA- β (1,6)-Gal G9	1.35	0	0	0	0 (**P<0.01)
4-Me-GlcA- β (1,6)-Prya n G10	1.35	83.3	11.5	6.674	0.9999993 (insignificant)
4-Me-GlcA-O-Me G11	1.35	23.3	5.8	3.337	0.0005656 (**P<0.01)

876